ANZ1001 SORBET: Study of Oestrogen Receptor Beta and Efficacy of Tamoxifen—A single-arm, phase II study of the efficacy of tamoxifen in triple-negative but oestrogen receptor beta-positive metastatic breast cancer.

Authors

B. E. Kiely

Australian New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle, Australia

B. E. Kiely , K. Phillips , P. A. Francis , F. M. Boyle , J. F. Forbes , S. B. Fox , L. Murphy , V. Gebski , D. F. Lindsay , R. L. Sutherland , H. Badger

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

Randomized phase II trial of venetoclax + fulvestrant versus fulvestrant in estrogen receptor+, HER2– locally advanced or metastatic breast cancer following recurrence or progression during or after a CDK4/6 inhibitor: VERONICA.

First Author: Geoffrey J Lindeman

insert_chart_outlined

Poster

2017 ASCO Annual Meeting

bookmark_border

Safety and efficacy of the BCL2 inhibitor venetoclax in estrogen receptor (ER) and BCL2-positive metastatic breast cancer: The mBEP study.

First Author: Geoffrey John Lindeman

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

A phase I/II trial evaluating the safety and efficacy of eribulin in combination with copanlisib in patients with metastatic triple-negative breast cancer (TNBC).

First Author: Nusayba Ali Bagegni

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine monotherapy for triple receptor-negative breast cancer (TNBC) with residual invasive cancer after neoadjuvant chemotherapy (MIRINAE trial, KCSG-BR18-21).

First Author: In Hae Park